Article info
PDFLeading article
The science, economics, and effectiveness of combination therapy for hepatitis C
- Conflict of interest statement.Professor Dusheiko has acted as a consultant for manufacturers of interferon, including Schering Plough, Roche and Yamanouchi/Amgen. He has received consultancy fees and honoraria to speak at symposia. His group undertakes research studies on alpha interferon and receives commercial research and development funding for this work. He currently holds 100 Schering Plough shares.
Citation
The science, economics, and effectiveness of combination therapy for hepatitis C
Publication history
- First published August 1, 2000.
Online issue publication
January 09, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
British Society of Gastroenterology